Yahoo Web Search

Sign In

Search results

  1. managinglymphoma.com › 20-martin-hutchingsMartin Hutchings, MD, PhD - Managing Lymphoma

    Dr. Hutchings is chairman of the Scientific Steering Committee for the EORTC Lymphoma Group and principal investigator for the EORTC H11 randomized trial.

    • Newsletters

      Join Dr. Shanbhag as he discusses the challenges in...

    • Contact Us

      ManagingLymphoma.com has been established to assist you in...

    • Follicular Lymphoma

      Spotlight on Relapsed/Refractory Follicular Lymphoma CME,...

    • About Us

      Managing Lymphoma is an educational online community for...

  2. Images

    • Martin Hutchings | Lymphoma Hub
    • Martin Hutchings on Hodgkin Lymphoma Brentuximab Vedotin With ...
    • Martin Hutchings, MD, PhD Rigshospitalet, Copenhagen Denmark 5Live # ...

    View all

  3. www.vjhemonc.com › speaker › martin-hutchingsMartin Hutchings | Videos & Research - VJHemOnc

    Jun 15, 2024 · Speaking on bispecific antibody treatment in patients with lymphoma. As well as treating patients with lymphoma, Dr Hutchings is a national principal investigator or sub-investigator in a variety of clinical trials investigating novel agents in solid and liquid malignancies.

    • Male
    • Danish

  4. www.researchgate.net › profile › Martin-HutchingsMartin HUTCHINGS | Senior consultant | MD PhD ... - ResearchGate

    Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and Previously...

  5. ascopost.com › videos › eha-2021-virtual-congressMartin Hutchings, MD, PhD, on Hodgkin Lymphoma: Brentuximab ...

    Martin Hutchings, MD, PhD, of Copenhagen University Hospital, discusses a 5-year update of the phase III ECHELON-1 study, which suggested brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine benefits patients with previously untreated stage III or IV classical Hodgkin lymphoma (Abstract S205).

  6. scholar.google.com › citations‪Martin Hutchings‬ - ‪Google Scholar‬

    Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic …

  7. www.ajmc.com › view › from-lymphomas-to-myeloma-biFrom Lymphomas to Myeloma, Bispecific Antibodies Make a Big ...

    Jan 14, 2023 · At ASH 2022, Martin Hutchings, MD, PhD, of Copenhagen University Hospital presented data in an oral session that focused on duration of CRs in patients with R/R LBCL after the end of treatment.

  8. ascopost.com › issues › february-10-2023Complete Response to Glofitamab at End of Treatment Heralds ...

    Feb 10, 2023 · Patients with large B-cell lymphoma who achieve a complete response to glofitamab are very likely to remain in remission 12 months after the end of treatment, according to Martin Hutchings, MD, PhD, of Rigshospitalet in Copenhagen, who reported these findings at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition. 1.